Telik Announces First Quarter 2012 Financial Results - Sacramento Bee
Telik Announces First Quarter 2012 Financial Results Sacramento Bee The company's most advanced drug candidate is TELINTRA, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by TELCYTA®, a cancer activated prodrug for the treatment of a ...